ClearPoint Neuro, Inc. (CLPT) Balance Sheet

The jump in total assets is largely financed by liabilities, which climbed from $13.8M to $85.5M over the same window, suggesting the expansion reflects external financing rather than operating strength. Retained earnings deteriorated every quarter, which indicates the company has not yet generated enough profit to offset its accumulated losses. Investors should monitor whether asset growth translates into a durable return on that capital base.

Leverage has risen sharply relative to the thin equity base, and the debt-to-equity ratio remains elevated even after the recent quarter's partial rebound in equity. Given persistent operating cash burn, the debt load appears to depend on continued access to capital markets, which warrants further investigation of repayment terms and maturities. The composition of this debt is not detailed in the supplied data, so refinancing risk cannot be fully assessed.

The asset base is not dominated by physical property, which is consistent with a business that is not heavily capital-intensive but still requires working capital to operate. The goodwill added in late 2025 introduces impairment exposure if the acquired business underperforms, though the amount is modest relative to total assets. The composition of the remaining non-PPE assets is not broken out in the supplied data, limiting precision on asset quality.

A current ratio near 7 indicates ample short-term liquidity on paper, but the ratio should be read alongside negative operating cash flow that consumes capital every quarter. Cash runway depends on the pace of operating burn, which the balance sheet alone cannot fully define. Investors should monitor whether the liquidity cushion is sustained as operating losses continue.